NovoCure Limited — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing provides annual results; it does not provide a clear standalone Q4 financial-results breakdown.
Business context
NovoCure develops and commercializes Tumor Treating Fields (TTFields) oncology devices. Its marketed products are Optune Gio for glioblastoma (GBM) and Optune Lua for malignant pleural mesothelioma (MPM). Most revenue is associated with Optune Gio. In December 2023, the company submitted an FDA premarket approval application for TTFields in metastatic non-small cell lung cancer (NSCLC); the FDA accepted it for filing in January 2024.
Key financial metrics
| U.S. dollars, millions, except per-share data | 2023 | 2022 | Change |
|---|---|---|---|
| Net revenue | $509.3 | $537.8 | (5%) |
| Gross profit / gross margin | $381.1 / 75% | $423.0 / 79% | Margin down 4 percentage points |
| Operating expenses | $613.9 | $512.5 | +20% |
| Operating loss | $(232.9) | $(89.5) | Loss widened |
| Net loss / loss per share | $(207.0) / $(1.95) | $(92.5) / $(0.88) | Loss widened |
| Adjusted EBITDA (non-GAAP) | $(106.3) | $28.1 | Down $134.3 |
| Operating cash flow | $(73.3) | $30.8 | Down $104.1 |
Revenue fell primarily because U.S. collections from denied or appealed claims decreased by $48.4 million, partly offset by improved reimbursement in Germany and the France launch. Revenue from successful appeals of previously denied Medicare fee-for-service claims declined to $5 million from $32 million; management says the most accessible claims were largely exhausted in 2022. Active patients at year-end increased to 3,755 from 3,430, while U.S. active patients were essentially flat at 2,162.
Cost of revenue rose 12%, and cost per active patient per month (excluding Zai sales) rose to $2,714 from $2,481, reflecting next-generation array costs and expanded patient-support capacity. R&D increased 8% to $223.1 million; sales and marketing rose 31% to $226.8 million; and general and administrative expense rose 24% to $164.1 million. Net financial income was $41.1 million, mainly reflecting higher investment income.
Liquidity, debt and other financial matters
- Year-end cash and cash equivalents were $240.8 million and short-term investments were $669.8 million, totaling $910.6 million, down $58.8 million from year-end 2022. Management expects these resources to fund operations for at least 12 months, while noting that expenses may continue to outpace gross profit and additional capital may be needed.
- Long-term debt, net, was $568.8 million, comprising $575 million principal of 0% convertible senior notes due November 2025. The notes are senior unsecured; the initial conversion price is approximately $168.24 per share. No balance remained under the terminated 2020 credit facility.
- Current assets were $1.034 billion and current liabilities were $179.1 million. The filing reports $43.1 million of supplier purchase obligations, including about $34.5 million with three major suppliers.
- Auditors issued unqualified opinions on the financial statements and internal control over financial reporting. Revenue estimation of variable consideration was identified as a critical audit matter.
Material changes, outlook and risks
- Management expects operating expenses to increase over the next several years and potentially outpace gross profit. It says future revenue should more closely reflect active patients, therapy duration and net realized monthly price as collections from older denied claims decline.
- The company plans continued commercial investment and NSCLC launch preparation. It anticipated an FDA decision on the NSCLC application in the second half of 2024. Top-line results were anticipated in Q1 2024 for the METIS brain-metastases trial and Q4 2024 for PANOVA-3 pancreatic cancer; final TRIDENT GBM data were anticipated in 2026.
- In November 2023, NovoCure announced a workforce reduction of about 200 employees, or 13% of the then-current workforce. It recorded $6.2 million of restructuring costs in 2023, partly offset by $9.3 million of forfeited equity compensation and $3.0 million of accrual reversals; total one-time costs were expected to be about $7 million across Q4 2023 and Q1 2024.
- The phase 3 INNOVATE-3 ovarian cancer trial did not meet its overall-survival primary endpoint. Conversely, LUNAR met its primary endpoint in NSCLC, with median overall survival of 13.2 months versus 9.9 months for standard therapy alone; results varied by treatment subgroup.
- A putative shareholder class action filed in 2023 alleges misstatements or omissions concerning LUNAR results. The company disputes the allegations; it recorded no liability because it judged loss was not probable and could not be reasonably estimated.
- Key risks include dependence on GBM revenue and reimbursement, uncertain regulatory approval and clinical outcomes, competition, single-source suppliers, product safety and quality, IP expirations and disputes, and execution of commercial expansion. The company also cites potential supply and operating disruption related to conflict in Israel and cybersecurity and privacy risks.
Important facts for investors to verify
- Whether NSCLC regulatory review, launch timing and reimbursement develop as anticipated.
- Whether patient growth and realized pricing can offset the decline in legacy U.S. claim collections and the lower gross margin.
- Cash burn, investment balances and funding requirements relative to the $575 million notes due in 2025.
- Upcoming clinical-trial results, particularly METIS and PANOVA-3, and any further analysis of the unsuccessful INNOVATE-3 trial.
- Developments in the LUNAR-related shareholder lawsuit, Medicare appeals, and supplier and Israel-related continuity risks.